Welcome to the APSA-ASCEPT 2017 Joint Scientific Meeting
On behalf of the Program Committee, we invite you to attend the APSA-ASCEPT Joint Scientific Meeting to be held at the Brisbane Convention & Exhibition Centre from 5 – 8 December 2017.
The theme for this meeting is Optimising medicines for optimal patient outcomes.
We anticipate that there will be approximately 400-450 attendees at the meeting from Australia, New Zealand, Asia, Europe and the United States. These world-class experts, early career researchers and students are all actively engaged in either academic or industrial pre-clinical and clinical pharmacology.
The meeting offers the opportunity to network with colleagues and other leading international and national scientists and academics at both social and scientific activities. A key feature of the meeting is the chance for early career researchers and research students to present their research findings in poster and oral presentations sessions. Annual awards and prizes from both APSA and ASCEPT will also be presented at this meeting.
The program of plenary lectures, symposia and workshops, oral presentations and posters will be scientifically stimulating and lead to new collaborations and research opportunities.
We welcome our many international guests and hope you will join us in Brisbane.
|Dr Stephanie Reuter Lange
|Prof Dom Geraghty
|Dr Andrew Crowe
|Assoc Prof Kevin Pfleger
Who should attend:
• academic and industrial scientists associated with drug discovery, drug formulation and drug delivery research and development
• clinicians involved in the prescription and/or review of therapeutic agents
• regulatory and clinical scientists involved in drug development and drug registration, bioavailability and bioequivalence study design and assessment, preparation and review of regulatory dossiers
• researchers in clinical pharmacy, pharmacology and toxicology
• education providers in pharmacy, pharmacology and toxicology
• students and postdoctoral fellows from Australia and New Zealand in all areas of pharmaceutical science and pharmacy
• government agencies involved in chemical safety assessment and registration
• medical practitioners such as clinical pharmacologists, clinical toxicologists, cardiologists and general physicians.